[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100542307":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":22,"responsibleParty":39,"collaborators":41,"id":48,"slug":10,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":10,"enrollmentInfo":57,"targetDuration":10,"studyType":60,"phases":10,"briefSummary":61,"conditions":62,"keywords":10,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},{"fullName":5,"class":6},"Centro Cardiologico Monzino","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Prospective Cohort",null,"Prospectively enrolled patients will undergo a complete assessment, as clinically indicated, including clinical evaluation, TTE, rest ECG, 24h ECG-monitoring, and CMR. CMR will be performed no more than 6 months apart from other examinations (TTE, rest ECG, 24h ECG-monitoring).",{"label":13,"type":10,"description":14,"interventionNames":10},"Retrospective Cohort","Patients will be enrolled retrospectively, in case they have already performed all examinations between 2016 and 2023",[16],{"name":17,"role":18,"phone":19,"phoneExt":20,"email":21},"Gianluca Pontone, MD","CONTACT","0258002574","+39","gianluca.pontone@cardiologicomonzino.it",[23],{"facility":5,"status":24,"city":25,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"RECRUITING","Milan","20131","Italy",{"type":29,"coordinates":30},"Point",[31,32],9.18951,45.46427,{"lat":32,"lon":31},[35],{"name":36,"role":18,"phone":37,"phoneExt":20,"email":38},"Chiara Centenaro","0258002031","chiara.centenaro@cardiologicomonzino.it",{"type":40,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[42,44,46],{"name":43,"class":6},"Humanitas Hospital, Italy",{"name":45,"class":6},"IRCCS Ospedale San Raffaele",{"name":47,"class":6},"Azienda Ulss 2 Marca Trevigiana","100542307",false,"NCT06341166","Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse","Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse: the SCIMITAR Trial","SCIMITAR","Inclusion Criteria:\n\n* age ≥ 18 years\n* Echocardiographic diagnosis of mitral valve prolaspe, defined as a systolic displacement of one or both mitral leaflets ≥ 2 mm above the plane of the mitral valve annulus in long-axis views\n\nExclusion Criteria:\n\n* age\\\u003C 18 years\n* coexistence of other cardiomyopathies or other ≥ moderate valve diseases\n* scarce acoustic transthoracic echocardiographic window\n* usual contraindications for cardiac magnetic resonance","ALL","18 Years",{"count":58,"type":59},300,"ESTIMATED","OBSERVATIONAL","This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP.",[63],"Mitral Valve Prolapse","2026-01-30",{"date":66,"type":67},"2026-02-03","ACTUAL",{"date":69,"type":67},"2023-06-19",{"date":71,"type":59},"2026-06-19",{"name":5,"class":6},1]